(DTRMWXHS-12 + everolimus + pomalidomide) is under clinical development by Zhejiang DTRM Biopharma and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (DTRMWXHS-12 + everolimus + pomalidomide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(DTRMWXHS-12 + everolimus + pomalidomide) overview
DTRM-555, a triplet combination of DTRMWXHS-12, everolimus and pomalidomide is under development for the treatment of relapsed and refractory chronic lymphocytic leukemia, activated B-cell (ABC) diffuse large B-cell lymphoma, germinal center B-cell (GCB) diffuse large B-cell lymphoma, Richter’s transformation and transformed follicular lymphoma. It is administered through oral route. DTRMWXHS-12 acts by targeting BTK. Everolimus act by targeting mTOR.
Zhejiang DTRM Biopharma overview
Zhejiang DTRM Biopharma, a biotechnology company that manufactures pharmaceutical products. The company is headquartered in United States.
For a complete picture of (DTRMWXHS-12 + everolimus + pomalidomide)’s drug-specific PTSR and LoA scores, buy the report here.